Brimapitide: Side Effects

Safety Overview#

Brimapitide demonstrated a favorable safety profile across all clinical trials. The drug and the intratympanic administration procedure were well-tolerated, with no drug-related serious adverse events reported in any study. Most adverse events were related to the injection procedure rather than the drug itself.

Clinical Trial Safety Data#

Phase 3 HEALOS Trial (PMID 31083077)#

• No drug-related serious adverse events
• Adverse events were primarily procedure-related
• Well-tolerated across 256 patients at 51 study sites
• No clinically significant differences in adverse event rates between AM-111 and placebo groups

Phase 2 Trial (PMID 24979398)#

• Drug and administration procedure were well-tolerated
• No drug-related serious adverse events
• Safety profile supported progression to Phase 3

Procedure-Related Effects#

The intratympanic injection procedure carries its own set of expected effects:

These procedural effects are well-characterized from intratympanic steroid injections, which are commonly performed in otology practice.

Safety Advantages of Local Delivery#

The intratympanic delivery route provided several safety advantages:

• No systemic exposure: The drug acts locally in the inner ear, eliminating the risk of systemic JNK inhibition
• Single dose: Only one injection was required, reducing cumulative procedural risk
• Biodegradable gel: The hyaluronic acid carrier is fully absorbed without requiring removal
• D-amino acid composition: The all-D configuration eliminates the risk of immune recognition or peptide-mediated allergic reactions

Theoretical Concerns Not Observed#

• JNK inhibition in non-target tissues: Not observed due to local delivery
• Immune-mediated reactions: Not reported (D-peptides are generally non-immunogenic)
• Ototoxicity from the formulation: Not observed; the hyaluronic acid gel was biocompatible

Safety Profile Context#

Brimapitide belongs to the Healing category of research peptides. Understanding the side effect profile of Brimapitide is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.

Reported Side Effects#

The following side effects have been documented in clinical studies of Brimapitide. Side effect severity and frequency are based on available clinical data.

Ear discomfort#

Severity: mild | Frequency: common

Transient discomfort in the treated ear following intratympanic injection. Associated with the procedure rather than the drug itself. Self-limiting.

Tympanic membrane perforation#

Severity: mild | Frequency: common

Small perforation from the injection procedure. Expected to heal spontaneously in most cases within days to weeks.

Dizziness/vertigo#

Severity: mild | Frequency: uncommon

Transient dizziness or vertigo following the intratympanic injection procedure. Typically resolves within minutes to hours.

Contraindications#

The following contraindications have been identified for Brimapitide based on available research and pharmacological considerations:

• Development discontinued. Formal contraindications were not established.
• Active middle ear infection would preclude intratympanic injection.
• Existing tympanic membrane perforation may affect gel retention and drug delivery.

Individuals with any of these conditions should not use Brimapitide without consulting a qualified healthcare provider.

Drug Interactions#

The following potential drug interactions have been identified for Brimapitide:

• No drug interactions were formally characterized. Local intratympanic administration minimizes systemic exposure and interaction potential.
• Concurrent systemic corticosteroid therapy (standard of care for ISSNHL) was not specifically contraindicated.

Drug interaction studies for Brimapitide remain limited. Researchers should exercise caution when combining Brimapitide with other compounds and consult relevant pharmacological references.

Related Reading#

• Brimapitide overview and research guide
• Brimapitide dosing protocols
• Brimapitide risks and legal status